연구동향 분석

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters

Gaurav Garg Kuruswamy Thurai Prasad Navneet Singh Parul Gupta Valliappan Muthu Ashim Das Amanjit Bal 년

논문상세정보
인용/피인용

' Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters' 의 참고문헌

  • Utility and safety of maintenance chemotherapy in advanced non-small cell lung cancer across various performance status categories : real-world experience
    Prasad KT [2020]
  • The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer
    Bremnes RM [2016]
  • The IASLC Lung Cancer Staging Project : proposals for the revision of the TNM stage groupings in the forthcoming(seventh)edition of the TNM classification of malignant tumours
    Goldstraw P [2007]
  • The 2015World Health Organization classification of lung tumors : impact of genetic, clinical and radiologic advances since the 2004 classification
    Travis WD [2015]
  • Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer : the global, multicenter EXPRESS study
    Dietel M [2019]
  • Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer : a multicenter study from India
    Patel A [2020]
  • Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer
  • Prognostic role of tumor-infiltrating lymphocytes in lung cancer : a metaanalysis
    Geng Y [2015]
  • Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer
    Brambilla E [2016]
  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042) : a randomised, open-label, controlled, phase 3 trial
    Mok TSK [2019]
  • Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
    Gandhi L [2018]
  • Pembrolizumab plus chemotherapy for squamous nonsmall-cell lung cancer
    Paz-Ares L [2018]
  • PD-L1 immunohistochemistry assays for lung cancer : results from phase 1 of the Blueprint PD-L1 IHC assay comparison project
    Hirsch FR [2017]
  • PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer : a comparative study
    Kim H [2017]
  • PD-L1 expression in lung cancer and its correlation with driver mutations : a meta-analysis
    Zhang M [2017]
  • PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy
    Sorensen SF [2016]
  • PD-1, PD-L1 protein expression in non-small cell lung cancer and their relationship with tumor-infiltrating lymphocytes
    He Y [2017]
  • P2.03-053 A five-year audit of EGFR and ALK testing at a tertiary care centre in North India: more sensitive methods do make a difference!
    Muthu V [2017]
  • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    Therasse P [2000]
  • Management of advanced lung cancer in resource-constrained settings : a perspective from India
    Singh N [2012]
  • Interconversion of two commonly used performance tools : an analysis of 5844 paired assessments in 1501 lung cancer patients
    Prasad KT [2018]
  • Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer
    Calles A [2015]
  • Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer
    Kumar M [2020]
  • Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1(PD-L1)on non-small cell lung carcinoma
    Parra ER [2018]
  • Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas : a report from India
  • Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer : a real-world multicentric cohort analysis from India
    Garg A [2020]
  • Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
    Socinski MA [2018]
  • Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer : an immunohistochemical study with clinicopathological and prognostic implications
    Mandarano M [2019]
  • Assessing tumor-infiltrating lymphocytes in solid tumors : a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group : Part 2 : TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors
    Hendry S [2017]
  • ALK gene rearranged lung adenocarcinomas : molecular genetics and morphology in cohort of patients from North India
    Bal A [2016]